Divi's Laboratories Limited (DIVISLAB.BO)
INR 5849.2
(0.02%)
INR 5849.2
(0.02%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 18.99 Billion INR | 13.6% |
| 2022 | 16.71 Billion INR | 1.53% |
| 2021 | 16.46 Billion INR | 11.29% |
| 2020 | 14.79 Billion INR | 20.7% |
| 2019 | 12.25 Billion INR | 13.38% |
| 2018 | 10.81 Billion INR | 25.56% |
| 2017 | 8.61 Billion INR | 7.48% |
| 2016 | 8.01 Billion INR | 31.59% |
| 2015 | 6.08 Billion INR | 8.6% |
| 2014 | 5.6 Billion INR | -24.97% |
| 2013 | 7.47 Billion INR | 17.08% |
| 2012 | 6.38 Billion INR | 2.08% |
| 2011 | 6.25 Billion INR | 30.97% |
| 2010 | 4.77 Billion INR | 39.95% |
| 2009 | 3.41 Billion INR | 11.14% |
| 2008 | 3.06 Billion INR | -3.3% |
| 2007 | 3.17 Billion INR | 2.98% |
| 2006 | 3.08 Billion INR | -0.34% |
| 2005 | 3.09 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -135.71 Billion INR | -814.64% |
| 2023 Q4 | 18.99 Billion INR | 0.0% |
| 2023 FY | 18.99 Billion INR | 13.6% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 16.06 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 16.71 Billion INR | 0.0% |
| 2022 FY | 16.71 Billion INR | 1.53% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 13.83 Billion INR | 0.0% |
| 2021 FY | 16.46 Billion INR | 11.29% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 15.1 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 16.46 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 14.79 Billion INR | 20.7% |
| 2020 Q4 | 14.79 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 12.01 Billion INR | 0.0% |
| 2019 FY | 12.25 Billion INR | 13.38% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 12.25 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 9.93 Billion INR | 0.0% |
| 2018 FY | 10.81 Billion INR | 25.56% |
| 2018 Q4 | 10.81 Billion INR | 0.0% |
| 2018 Q1 | - INR | 0.0% |
| 2017 FY | 8.61 Billion INR | 7.48% |
| 2016 FY | 8.01 Billion INR | 31.59% |
| 2015 FY | 6.08 Billion INR | 8.6% |
| 2014 Q4 | 9.09 Billion INR | 0.0% |
| 2014 FY | 5.6 Billion INR | -24.97% |
| 2013 Q4 | 7.47 Billion INR | 0.0% |
| 2013 FY | 7.47 Billion INR | 17.08% |
| 2012 FY | 6.38 Billion INR | 2.08% |
| 2012 Q4 | 6.38 Billion INR | 0.0% |
| 2011 FY | 6.25 Billion INR | 30.97% |
| 2010 FY | 4.77 Billion INR | 39.95% |
| 2009 FY | 3.41 Billion INR | 11.14% |
| 2008 FY | 3.06 Billion INR | -3.3% |
| 2007 FY | 3.17 Billion INR | 2.98% |
| 2006 FY | 3.08 Billion INR | -0.34% |
| 2005 FY | 3.09 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Ajanta Pharma Limited | 10.71 Billion INR | -77.306% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -2322.738% |
| Sigachi Industries Limited | 2.53 Billion INR | -650.218% |
| Bal Pharma Limited | 2.51 Billion INR | -656.189% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -729.453% |
| Medico Remedies Limited | 438.24 Million INR | -4233.203% |
| Lasa Supergenerics Limited | 541.92 Million INR | -3404.175% |
| Venus Remedies Limited | 1.39 Billion INR | -1263.441% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -387.811% |
| Alpa Laboratories Limited | 307.12 Million INR | -6083.211% |
| Nectar Lifesciences Limited | 11.21 Billion INR | -69.28% |
| Shilpa Medicare Limited | 12.93 Billion INR | -46.84% |
| Aarti Drugs Limited | 11.5 Billion INR | -65.073% |
| Lupin Limited | 96.23 Billion INR | 80.268% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 87.524% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 73.549% |
| Windlas Biotech Limited | 1.76 Billion INR | -977.325% |
| Suven Life Sciences Limited | 148.62 Million INR | -12677.468% |
| Eris Lifesciences Limited | 38.26 Billion INR | 50.376% |
| Valiant Laboratories Limited | 1.05 Billion INR | -1694.457% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | -77.344% |
| Solara Active Pharma Sciences Limited | 14.14 Billion INR | -34.264% |
| Ipca Laboratories Limited | 33.74 Billion INR | 43.721% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -800.49% |
| Achyut Healthcare Limited | 2.01 Million INR | -943268.107% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 89.655% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -290.125% |
| RPG Life Sciences Limited | 1.38 Billion INR | -1275.888% |
| Mankind Pharma Limited | 23.87 Billion INR | 20.46% |
| Laurus Labs Limited | 42.71 Billion INR | 55.542% |
| Piramal Pharma Limited | 74 Billion INR | 74.339% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -1529.748% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 76.856% |
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | -16.691% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 70.834% |
| Unichem Laboratories Limited | 8.06 Billion INR | -135.338% |
| Sequent Scientific Limited | 8.27 Billion INR | -129.507% |
| Novartis India Limited | 1.8 Billion INR | -954.356% |
| Wanbury Limited | 3.15 Billion INR | -501.803% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -833.523% |
| Wockhardt Limited | 39.87 Billion INR | 52.37% |
| Themis Medicare Limited | 1.88 Billion INR | -906.087% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -6299.11% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 69.008% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -266.539% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 82.247% |
| NATCO Pharma Limited | 10.53 Billion INR | -80.308% |
| Gufic Biosciences Limited | 5.59 Billion INR | -239.119% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -200.052% |
| Ind-Swift Limited | 13.45 Billion INR | -41.158% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -641.449% |
| FDC Limited | 3.7 Billion INR | -411.969% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -538.552% |
| Granules India Limited | 22.95 Billion INR | 17.271% |
| Medicamen Biotech Limited | 940.36 Million INR | -1919.424% |
| Alkem Laboratories Limited | 48.6 Billion INR | 60.93% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -418.695% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -6475.508% |
| Brooks Laboratories Limited | 248.6 Million INR | -7538.746% |
| Megasoft Limited | 1.85 Billion INR | -924.746% |
| ZIM Laboratories Limited | 2.08 Billion INR | -812.646% |
| Strides Pharma Science Limited | 37.68 Billion INR | 49.603% |
| Neuland Laboratories Limited | 5.49 Billion INR | -245.363% |
| Morepen Laboratories Limited | 4.45 Billion INR | -325.805% |
| Hikal Limited | 12.99 Billion INR | -46.134% |
| Indoco Remedies Limited | 10.34 Billion INR | -83.615% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | -130.162% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -2849.294% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -860.881% |
| Hester Biosciences Limited | 3.59 Billion INR | -428.275% |